Veltuzumab
Humanized (from mouse) | |
---|---|
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6458H9918N1706O2026S46 |
Molar mass | 145349.06 g·mol−1 |
(what is this?) (verify) |
Veltuzumab is a
This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]
In August 2015 the
See also
- CD20 antagonist
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
- PMID 19710501.
- ^ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
- PMID 25847298.
- ISBN 978-3-527-68244-7.
- ^ a b "FDA grants orphan drug designation to veltuzumab for ITP". HemOnc Today. Healio.com. August 4, 2015.